Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
NCT03635567
Completed
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin with or without bevacizumab and paclitaxel plus carboplatin with or without bevacizumab. The prim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Alaska Women's Cancer Care ( Site 1770), Anchorage, Alaska +148 locations
Conditions: Cervical Cancer
Register for Updates
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03776812
Completed
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Site Reference ID/Investigator #004, Birmingham, Alabama +23 locations
Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
NCT04999969
Active Not Recruiting
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/23/2025
Locations: Research Site, La Jolla, California +33 locations
Conditions: Locally Advanced or Metastatic Solid Tumours
Register for Updates
A Study of LY3200882 in Participants With Solid Tumors
NCT02937272
Active Not Recruiting
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: University of Louisville, Louisville, Kentucky +17 locations
Conditions: Solid Tumor
Register for Updates
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
NCT05257408
Active Not Recruiting
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Site 318, Phoenix, Arizona +116 locations
Conditions: Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Register for Updates
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
NCT06783140
Not Yet Recruiting
This study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Pancreatic Cancer, Advanced or Metastatic, BRCA1/2 Mutation, PALB2 Gene Mutation
Register for Updates
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883
Recruiting
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/26/2025
Locations: Arizona Oncology Associates Professional Corporation, Tucson, Arizona +89 locations
Conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Register for Updates
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
NCT02879318
Completed
The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Tom Baker Cancer Centre, Calgary, Alberta +26 locations
Conditions: Pancreatic Adenocarcinoma
Register for Updates
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
NCT03568422
Active Not Recruiting
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer. One of the standard types of chemotherapy is a drug called paclitaxel (Taxol) given in a low dose every week for three out of four weeks. CFI-402257 is a new type of drug for breast cancer. Laboratory tests show that it may help slow the growth of breast cancer. This drug has been shown to shrink tumours in animals. CFI-402257 has been studied in a few p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: BCCA - Vancouver Cancer Centre, Vancouver, British Columbia +3 locations
Conditions: Breast Cancer
Register for Updates
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
NCT03798626
Completed
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/06/2025
Locations: University of California LA, Los Angeles, California +33 locations
Conditions: Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
Register for Updates
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
NCT04460352
Recruiting
NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention definitive chemoradiotherapy. A second co-primary endpoint is global health related quality of life (HRQOL) one year after randomisation. A third co-primary endpoint is eating restictions one year after randomisation. The aim is to compare outcomes after neoadjuvant chemor... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/04/2025
Locations: McGill University Health Centre, Montréal, Quebec +11 locations
Conditions: Esophageal Squamous Cell Carcinoma
Register for Updates
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
NCT00667251
Completed
This was a multi-center, multinational, randomized, open-label, Phase III study comparing combination taxane-based chemotherapy plus lapatinib to combination taxane-based chemotherapy plus trastuzumab in women with documented evidence of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) (by local or central laboratory testing) who had received no prior chemotherapy or HER2 targeted therapy in the metastatic setting.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Novartis Investigative Site, Anchorage, Alaska +257 locations
Conditions: Breast Cancer
Register for Updates